Epizyme (NASDAQ:EPZM) had its target price raised by equities researchers at Leerink Swann from $22.00 to $24.00 in a report issued on Wednesday, March 14th. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Swann’s price target would indicate a potential upside of 26.05% from the company’s current price. Leerink Swann also issued estimates for Epizyme’s Q1 2018 earnings at ($0.54) EPS, Q2 2018 earnings at ($0.58) EPS, Q3 2018 earnings at ($0.55) EPS, Q4 2018 earnings at ($0.63) EPS, FY2018 earnings at ($2.31) EPS, FY2019 earnings at ($2.90) EPS, FY2020 earnings at ($1.98) EPS, FY2021 earnings at $0.28 EPS and FY2022 earnings at $3.46 EPS.
Several other research firms have also commented on EPZM. BidaskClub upgraded Epizyme from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 5th. Cann restated a “buy” rating and set a $26.00 target price on shares of Epizyme in a research report on Tuesday, December 12th. Oppenheimer set a $26.00 target price on Epizyme and gave the company a “buy” rating in a research report on Tuesday, December 12th. Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, Morgan Stanley initiated coverage on Epizyme in a report on Wednesday, January 10th. They issued an “overweight” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $23.50.
Shares of Epizyme (NASDAQ EPZM) traded up $0.04 during trading on Wednesday, reaching $19.04. The company had a trading volume of 56,220 shares, compared to its average volume of 461,675. The company has a market cap of $1,295.06, a PE ratio of -8.68 and a beta of 2.00. Epizyme has a one year low of $9.30 and a one year high of $21.40.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.05. Epizyme’s revenue for the quarter was down 100.0% on a year-over-year basis. research analysts anticipate that Epizyme will post -2.37 EPS for the current fiscal year.
In other news, COO Matthew Ros sold 72,264 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the sale, the chief operating officer now directly owns 74,867 shares of the company’s stock, valued at $1,245,038.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 25.20% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC purchased a new stake in Epizyme in the fourth quarter valued at $263,000. Palo Alto Investors LLC boosted its stake in shares of Epizyme by 7.2% during the 4th quarter. Palo Alto Investors LLC now owns 6,860,843 shares of the biopharmaceutical company’s stock worth $86,104,000 after acquiring an additional 462,547 shares in the last quarter. Redmile Group LLC boosted its stake in shares of Epizyme by 59.1% during the 4th quarter. Redmile Group LLC now owns 1,925,689 shares of the biopharmaceutical company’s stock worth $24,167,000 after acquiring an additional 715,689 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of Epizyme by 100.7% during the 4th quarter. Macquarie Group Ltd. now owns 82,485 shares of the biopharmaceutical company’s stock worth $1,035,000 after acquiring an additional 41,385 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Epizyme by 56.4% during the 4th quarter. Millennium Management LLC now owns 996,687 shares of the biopharmaceutical company’s stock worth $12,508,000 after acquiring an additional 359,547 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Leerink Swann Boosts Epizyme (EPZM) Price Target to $24.00” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/03/21/epizymes-epzm-buy-rating-reaffirmed-at-leerink-swann.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.